Autologous Adipose Mesenchymal Stem Cell Transplantation in the Treatment of Patients With Hemifacial Spasm

Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Other)
Overall Status
Unknown status
CT.gov ID
NCT02853942
Collaborator
(none)
100
2
14

Study Details

Study Description

Brief Summary

Main purpose:In the face of listening to nerve injury at early stage, utilizing autologous adipose stem cell transplantation in the treatment of makes the acceptance micro vascular decompression hemifacial spasm patients to nerve function to obtain a better recovery.

Secondary purpose :To clarify the efficacy of stem cells in the treatment of cranial nerve dysfunction, and to provide evidence for the treatment of other cranial nerve dysfunction.

Cases in group:Appearing on the surface of microvascular decompression for hemifacial spasm to decrease neural electrophysiological index of patients research design:Single center, prospective, randomized, double-blind, controlled Observation index:Facial nerve clinical score, facial nerve muscle compound action potential, electrical measurement, cerebrospinal fluid index Evaluation of therapeutic effect:Facial nerve function evaluation (House-Brackmann classification, facial nerve function classification scale SFGS), facial nerve electrophysiology evaluation (facial nerve muscle compound action potential), electric measurement Safety evaluation:Clear evaluation of hemifacial spasm and micro vascular decompression were listening to nerve in intracranial segment wrapped around the autologous fat stem cell therapy overall safety and evaluation methods including adverse events, laboratory tests, vital signs, electrocardiogram.

Condition or Disease Intervention/Treatment Phase
Early Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
The Research of Autologous Adipose Mesenchymal Stem Cell Transplantation for Treatment of Facial 、Auditory Nerve Dysfunction of Patients With Hemifacial Spasm After Microvascular Decompression.
Study Start Date :
Oct 1, 2016
Anticipated Primary Completion Date :
Oct 1, 2017
Anticipated Study Completion Date :
Dec 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Stem cell therapy group

Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.

Biological: Autologous adipose stem cell therapy

Drug: Mecobalamin

Experimental: Neurotrophic drugs treatment group

Patients were treated with routine drug therapy,do not inject stem cell to the facial nerve of patient

Drug: Mecobalamin

Outcome Measures

Primary Outcome Measures

  1. House-Brackmann facial nerve grading scale [up to 3 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. the age of 18 ~ 80 years old;

  2. no surgical contraindications, accept facial nerve microvascular decompression surgery;

  3. to enter into the group's informed consent and sign the consent form for clinical research.

  4. patients with preoperative facial nerve electrophysiology examination without facial paralysis

  5. patients with preoperative electrical testing without hearing impairment

Exclusion Criteria:
  1. patients with poor compliance;

  2. major surgical complications and interruption of treatment;

  3. brain magnetic resonance examination or blood test results abnormal and clinical significance;

  4. clinical trials of other drugs within 30 days;

  5. the unintended side effects;

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shiting Li, Office of clinical research of Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier:
NCT02853942
Other Study ID Numbers:
  • XH-16-012
First Posted:
Aug 3, 2016
Last Update Posted:
Aug 9, 2016
Last Verified:
Aug 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 9, 2016